Ibogaine Faces New Federal Attention as Trump Weighs Executive Order
Washington, April 16, 2026, 11: 51 AM ET — The White House is drafting an executive order that would signal the Trump administration’s willingness to expand U. S. research into ibogaine, a psychedelic compound used in some countries to treat post-traumatic stress disorder. The move could come as soon as this week, and it would focus federal attention on the drug’s safety and effectiveness without changing its legal status. For now, ibogaine would remain a Schedule I substance in the United States.
Federal review could open the door to more research
The planned order is expected to encourage further study of ibogaine for PTSD and traumatic brain injuries, especially among veterans. Officials familiar with the discussions said the administration is not planning to reclassify the drug for medical use at this time, even as it considers ways to support research.
Ibogaine is a naturally occurring compound from a shrub native to Africa. In countries where it is used, it has been associated with treatment efforts for depression, anxiety, addiction, PTSD and brain trauma. In the United States, however, the drug remains illegal, which has pushed some Americans to seek treatment at unregulated clinics, often in Mexico or the Caribbean.
The administration’s interest appears tied to a broader effort to determine whether the drug has legitimate medical value or is, in the words of one official, “snake oil. ” Internal discussions this week were still working out how federal agencies might facilitate further research.
Ibogaine research remains early and limited
The scientific record behind ibogaine is still narrow. Most of the evidence now available comes from small observational studies and open-label trials, and only one double-blind, placebo-controlled randomized clinical trial has been completed. More advanced trials are just getting underway, researchers said.
The biggest concern is safety, particularly for the heart. Ibogaine can trigger dangerous heart rhythm disturbances that can be fatal. A 2023 review of 24 studies involving 705 people found signs that the drug may reduce withdrawal symptoms and craving, but it also flagged heart toxicity and the risk of death as worrying. That review said at least 27 people have died after taking ibogaine.
At the same time, a small study of 30 veterans that paired the drug with intravenous magnesium reported no serious cardiac events. The study, published last July by Stanford Medicine, found that ibogaine appeared to reduce PTSD, anxiety and depression in veterans when combined with magnesium, but the sample was too small and lacked a placebo group, leaving major questions unresolved.
Officials, veterans and states are pushing the issue
Texas has become a major state-level driver of ibogaine research. Gov. Greg Abbott last year signed a bill approving $50 million for research, underscoring the growing political interest in the compound.
White House spokespeople did not immediately comment on the draft order. Several the administration’s current goal is to open the door to federal funding for further research, rather than to approve the drug for medical use.
The topic has also drawn attention because of veterans seeking treatment outside the United States. Last year, a televised segment followed a group of nine U. S. veterans who traveled to a remote village near Puerto Vallarta, Mexico, for a week-long psychedelic retreat aimed at easing intrusive memories.
What happens next
If the executive order is signed this week, the next phase will likely center on how federal agencies structure support for more studies and how quickly that research can move forward. For now, ibogaine sits at the center of a sharp debate: whether a drug still banned in the United States could eventually prove useful in treating PTSD, addiction and brain trauma, or whether the existing evidence remains too thin to justify wider pursuit.
